PS1 Phase 3 KEYNOTE-042 Study: Pembrolizumab vs Platinum-Based Chemotherapy as 1l Therapy for Advanced NSCLC with a PD-L1 TPS ≥1%

Lopes, G. and Wu, Y. and Kudaba, I. and Kowalski, D. and Cho, B. and Turna, H. and De Castro, G. and Srimuninnimit, V. and Laktionov, K. and Bondarenko, I. and Kubota, K. and Lubiniecki, G. and Zhang, J. and Kush, D. and Mok, T. (2018) PS1 Phase 3 KEYNOTE-042 Study: Pembrolizumab vs Platinum-Based Chemotherapy as 1l Therapy for Advanced NSCLC with a PD-L1 TPS ≥1%. Journal of Thoracic Oncology, Vol.13 (No. 9S). S152-S154. ISSN 1556-0864

Text PIIS1556086418308153.pdf Download (160kB)

Abstract

First-line (1L) therapy with pembrolizumab in patients with metastatic NSCLC without targetable aberrations and programmed death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50% significantly improved the primary endpoint of PFS, and OS (secondary endpoint) compared to chemotherapy in the KEYNOTE-024 study. In KEYNOTE-042 (NCT02220894), we evaluated pembrolizumab vs chemotherapy at the lower PD-L1 TPS of ≥1%.

Item Type:	Article
Additional Information:	PRESIDENTIAL SYMPOSIUM| VOLUME 13, ISSUE 9, SUPPLEMENT , S152, SEPTEMBER 01, 2018 https://www.jto.org/article/S1556-0864(18)30815-3/fulltext https://doi.org/10.1016/j.jtho.2018.07.020
Uncontrolled Keywords:	chemotherapy, KEYNOTE-042, programmed death ligand 1 (PD-L1), pembrolizumab
Subjects:	Oncology
Divisions:	Departments > Department of Oncology and Medical Radiology
Depositing User:	Елена Шрамко
Date Deposited:	01 Mar 2021 15:47
Last Modified:	01 Mar 2021 15:52
URI:	http://repo.dma.dp.ua/id/eprint/6283

Actions (login required)

View Item